Clinical trials: Oral Neoplasm
Liver Cancer, Hepatocellular Carcinoma
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver Fibrosis
- Trial name
- IMPACT (NCT00151671)
- Testing
- Oral Impact®
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Xerostomia
Interest of Auriculotherapy in the Treatment of Xerostomia
The aim of the study is to show that auriculotherapy is effective in the treatment of xerostomia
- Trial name
- AURICULOXERO (NCT04222478)
- Testing
- Specific auriculotherapy, Non-specific auriculotherapy
- Where
- 4 sites in France
- Volunteers
- 65 people
- Sponsor
- Hopital Foch
Liver Cancer
Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)
To evaluate the additional efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced liver cancer and treated with tyrosine kinase inhibitors (TKIs) combined with immunotherapy.
- Trial name
- NCT06563934
- Testing
- Oral enterobacterium capsules, Lenvatinib + PD-1 monoclonal antibody
- Volunteers
- 70 people
- Sponsor
- Xu Yong, MD
Tongue Cancer
Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer
Surgical excision is the mainstay of treatment for tongue cancer. However, surgery-induced immunosuppression has been implicated in the development of post-operative septic complications and neoplasm metastasis.
- Trial name
- NCT01854021
- Testing
- intravenous anesthesia, combined intravenous-inhalational anesthesia, inhalational anesthesia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- tiejun Zhang
Neoplasms
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT00559533
- Testing
- RO5045337
- Where
- 7 sites in United States, France
- Volunteers
- 106 people
- Sponsor
- Hoffmann-La Roche
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor…
- Trial name
- NCT04505826
- Testing
- OP-1250
- Where
- 19 sites in United States, Australia
- Volunteers
- 153 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Lymphoma, Cancer
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
- Conditions
- Lymphoma, Cancer, Thyroid Carcinoma
- Trial name
- NCT00215605
- Testing
- XL184
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Exelixis
Osteoporosis
Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
Multi-center,double blind randomized phase III placebo controlled study in 250 men with histologically proven prostate cancer with out bone metastases who are beginning ADT therapy and who will receive concomitant treatment with…
- Trial name
- NCT00236002
- Testing
- Alendronate
- Volunteers
- 182 people
- Sponsor
- Canadian Urology Research Consortium
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Malignant Oral Cavity Neoplasm, Malignant Skull Base Neoplasm
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
This phase IV trial studies how well serial magnetic resonance imaging (MRI) after radiation therapy works in predicting radiation-induced changes in the normal tissue of patients with oral cavity or skull base tumors.
- Conditions
- Malignant Oral Cavity Neoplasm, Malignant Skull Base Neoplasm, Osteoradionecrosis
- Trial name
- NCT04265430
- Testing
- Contrast Agent, Magnetic Resonance Imaging, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 425 people
- Sponsor
- M.D. Anderson Cancer Center
Muscle Invasive Bladder Cancer
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
This trial is designed to evaluate the safety, efficacy, and biomarker response of APL-1202 in combination with tislelizumab as neoadjuvant therapy for patients with MIBC who are cisplatin ineligible or refuse cisplatin-based…
- Trial name
- ANTICIPATE (NCT04813107)
- Testing
- APL-1202 in combination with tislelizumab, Tislelizumab alone
- Where
- 2 sites in United States, China
- Volunteers
- 79 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Tumors
A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
Confirmation of BIBF 1120 administered from 150 mg twice daily (b.i.d.) to 250 mg b.i.d. as safe and tolerable treatment in Japanese patients with advanced solid tumours, overall safety, pharmacokinetic parameters, biomarkers…
- Trial name
- NCT02182128
- Testing
- BIBF 1120
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003602
- Testing
- cytarabine, etoposide, idarubicin
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Riverside Haematology Group
Head and Neck Cancer
Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area
The purpose of this clinical investigation is to evaluate acute and longlasting side effects in patients undergoing radiotherapy for cancer treatment in the head and neck area.
- Trial name
- NCT00995319
- Where
- Norway
- Volunteers
- 58 people
- Sponsor
- Norwegian University of Science and Technology
Colorectal Cancer, Glucometabolic Response
The Effect of Oral Carbohydrate Administration on Postoperative Well-being
Studies have shown that clear liquids containing carbohydrates are safe when given up to 2 hours before surgery and increase patient comfort before surgery.
- Conditions
- Colorectal Cancer, Glucometabolic Response, Subjective Goodness, Life Quality
- Trial name
- NCT05402592
- Testing
- Carbonhydrate rich drink, Water
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Muğla Sıtkı Koçman University
Lymphoma, Large B-Cell, Diffuse
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of GVD±R (gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab) regimen for autologous…
- Trial name
- NCT04021992
- Testing
- gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Oral Mucositis
Oral Care With Propolis in Pediatric Oncology Patients
According to the data from the World Health Organization, approximately 14 million people are diagnosed with cancer every year, and this number is expected to increase further in the next 10 years.
- Trial name
- NCT05400031
- Testing
- propolis
- Where
- Turkey (Türkiye)
- Volunteers
- 108 people
- Sponsor
- Izmir Katip Celebi University
Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
This is a monocentric, non-randomized, prospective, in silico feasibility study conducted by Strasbourg Europe Cancerology Institute.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- OPPIDOM (NCT04801472)
- Testing
- Optimisation of dental implant sites protection from irradiation
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Institut de cancérologie Strasbourg Europe